In short
Clinical trials are studying Vx-264 in people with type 1 diabetes. These studies aim to check safety, tolerability, and early signs of benefit, including how the body responds over time. The target group is subjects with type 1 diabetes mellitus.
Key points
- Clinical trials of Vx-264 are studying people with type 1 diabetes mellitus. The main goal is to check safety and tolerability, and to look for early signs that the study treatment may help. This is a Phase 1/2 interventional study, so it is still in an early research stage. The trial plans to enroll 17 subjects. The study also measures lab tests, vital signs, ECGs, imaging, eye checks, and peak C-peptide after a mixed meal test at Day 90.
Trial overview
This clinical trial is an interventional study, which means researchers are giving a study treatment and then watching what happens. The study is titled “A Safety, Tolerability, and Efficacy Study of VX-264 in Subjects With Type 1 Diabetes.” It is currently listed as Authorised and plans to enroll 17 subjects.
Who is being studied
The target population is people with type 1 diabetes mellitus. In the trial record, the condition is listed as Type 1 Diabetes Mellitus, and the brief summary says the study is evaluating Vx-264 in subjects with T1D. The source data do not provide more detailed participation rules such as age limits or other entry requirements.
Study design and phase
The study is in Phase 1/2, which is an early research stage. Phase 1/2 studies usually focus first on safety, then begin to look for early signs that the treatment may help. The intervention listed is a VX-264 Implant given by implantation.
The trial has multiple parts, including Part A, Part B, and Part C. The source data show that Part A and Part B focus on safety and tolerability, while Part C looks at a measure of function called peak C-peptide during a mixed meal tolerance test at Day 90.
What the trial measures
The main outcomes in Parts A and B are safety and tolerability. Safety is checked by looking at treatment-emergent adverse events, serious adverse events, adverse device effects, serious adverse device events, and device deficiencies. The study also includes clinical laboratory tests, vital signs, standard 12-lead ECGs, imaging with ultrasound and magnetic resonance imaging, and retinopathy evaluation.
The trial also records how many subjects receive less than the target number of VX-264 units because of adverse events or adverse device effects. It also tracks how many subjects have VX-264 units explanted, which means removed, because of adverse events, adverse device effects, or unit integrity issues. In Part C, the main measure is the change from baseline in peak C-peptide during the mixed meal tolerance test at Day 90.
What the results may show
Based on the trial design, this study is mainly trying to learn whether Vx-264 can be used safely in people with type 1 diabetes. It is also looking for early signs of function, measured by C-peptide, which can help show whether the body is making insulin. Because this is an early-phase study with 17 subjects, it is not designed to give a final answer about long-term benefit.